ALT — Altimmune, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326190 ·
Last close
$2.84
Market Cap
$552.31M
52W High
$3.40
52W Low
$2.56
ADV30
4,908,483
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -24,244,000 | -22,563,000 | 335,630,000 | 97,601,000 | 51,643,000 |
| Dec 2025 | 26,000 | — | -28,893,000 | -27,358,000 | 279,929,000 | 43,760,000 | 55,037,000 |
| Sep 2025 | 5,000 | — | -20,859,000 | -19,014,000 | 218,447,000 | 61,236,000 | 32,846,000 |
| Jun 2025 | 5,000 | — | -22,922,000 | -22,146,000 | 190,350,000 | 183,105,000 | 28,983,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-71,637,000
Investing CF
$-131,062,000
Financing CF
$251,196,000
CapEx
$-22,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-672,046,000
Inventory
—
Receivables
$1,665,000
ST Investments
$233,939,000
EBIT TTM
$-88,378,000
Pretax Income TTM
$-91,081,000
Interest Exp TTM
$2,703,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,000
EBITDA
$-96,103,000
Free Cash Flow
$-42,502,000
Enterprise Value
$256,613,600
Total Cash
$331,540,000
Total Debt
$35,847,000
Shares Out
194,474,154
Trailing EPS
$-0.92
Book Value
$2.18
ROE
-42.7%
ROA
-24.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 41,000 | -94,489,000 | -88,093,000 | 279,929,000 | 55,037,000 | — | -67,535,000 |
| Dec 2024 | 20,000 | -103,172,000 | -95,059,000 | 139,306,000 | 15,798,000 | — | -79,848,000 |
| Dec 2023 | 426,000 | -83,510,000 | -88,447,000 | 210,640,000 | 16,541,000 | — | -75,810,000 |
| Dec 2022 | -68,000 | -87,740,000 | -84,713,000 | 206,928,000 | 21,635,000 | — | -62,586,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$371,000
NetIncome TTM
$-90,548,000
OpCashFlow TTM
$0
Assets (Latest)
$139,306,000
Forward EPS
$-0.69
Max Pain — expiry 2026-08-21
max pain strike: $3.00 · spot: $2.84 · call oi: 17,419 · put oi: 2,124
Expected Move to 2026-08-21:
±$0.50
(17.61%) —
implied range
$2.34 –
$3.34
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | $554.89M | $13.02 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $557.48M | $5.31 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $562.18M | $9.51 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $537.47M | $14.47 | — |
| ARVN | ARVINAS, INC. | $518.11M | $8.03 | — |
News headlines (Yahoo Finance, 1h cache)
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff
2026-07-28 18:42 · Yahoo
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
2026-07-28 14:04 · Yahoo
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%
2026-07-28 12:33 · Yahoo
Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results
2026-07-28 12:22 · Yahoo
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market
2026-07-05 22:08 · Yahoo
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
2026-06-26 08:59 · Yahoo
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?
2026-06-24 13:26 · Yahoo
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data
2026-06-17 15:16 · Yahoo
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
2026-06-12 15:30 · Yahoo
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near
2026-06-10 13:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.